QRG Capital Management Inc. Sells 22,874 Shares of Thermo Fisher Scientific Inc. $TMO

QRG Capital Management Inc. cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 51.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,933 shares of the medical research company’s stock after selling 22,874 shares during the quarter. QRG Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $8,893,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. ZWJ Investment Counsel Inc. raised its position in shares of Thermo Fisher Scientific by 6.1% in the second quarter. ZWJ Investment Counsel Inc. now owns 82,548 shares of the medical research company’s stock valued at $33,470,000 after purchasing an additional 4,778 shares during the period. Barrett & Company Inc. increased its position in Thermo Fisher Scientific by 377.4% during the second quarter. Barrett & Company Inc. now owns 253 shares of the medical research company’s stock worth $103,000 after acquiring an additional 200 shares during the period. Two Point Capital Management Inc. bought a new position in Thermo Fisher Scientific during the second quarter worth about $4,143,000. Ameritas Advisory Services LLC increased its position in Thermo Fisher Scientific by 5.1% during the second quarter. Ameritas Advisory Services LLC now owns 3,991 shares of the medical research company’s stock worth $1,618,000 after acquiring an additional 195 shares during the period. Finally, HighMark Wealth Management LLC increased its position in Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 3.6%

TMO opened at $543.88 on Friday. The company’s 50 day moving average is $482.58 and its 200-day moving average is $447.27. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $205.37 billion, a P/E ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.95%.

Insider Activity

In related news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $56,937,881. This trade represents a 0.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on TMO shares. Robert W. Baird raised their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research report on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a research report on Friday, July 11th. HSBC reissued a “hold” rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Finally, William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating on the stock. Fifteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $585.37.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.